CN115315264A - 人参皂苷组合物 - Google Patents

人参皂苷组合物 Download PDF

Info

Publication number
CN115315264A
CN115315264A CN202180022225.5A CN202180022225A CN115315264A CN 115315264 A CN115315264 A CN 115315264A CN 202180022225 A CN202180022225 A CN 202180022225A CN 115315264 A CN115315264 A CN 115315264A
Authority
CN
China
Prior art keywords
ginsenosides
weight
composition
gut microbiota
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180022225.5A
Other languages
English (en)
Chinese (zh)
Inventor
R·莱克赞奈特
P·E·R·方卡-贝尔东
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Givaudan SA
Original Assignee
Givaudan SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004121.6A external-priority patent/GB202004121D0/en
Priority claimed from GBGB2005288.2A external-priority patent/GB202005288D0/en
Application filed by Givaudan SA filed Critical Givaudan SA
Publication of CN115315264A publication Critical patent/CN115315264A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CN202180022225.5A 2020-03-20 2021-03-17 人参皂苷组合物 Pending CN115315264A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB2004121.6 2020-03-20
GBGB2004121.6A GB202004121D0 (en) 2020-03-20 2020-03-20 Improved compositions
GB2005288.2 2020-04-09
GBGB2005288.2A GB202005288D0 (en) 2020-04-09 2020-04-09 Improved compositions
PCT/EP2021/056803 WO2021185897A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Publications (1)

Publication Number Publication Date
CN115315264A true CN115315264A (zh) 2022-11-08

Family

ID=75108332

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202180022225.5A Pending CN115315264A (zh) 2020-03-20 2021-03-17 人参皂苷组合物
CN202180022249.0A Pending CN115315266A (zh) 2020-03-20 2021-03-17 人参皂苷组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180022249.0A Pending CN115315266A (zh) 2020-03-20 2021-03-17 人参皂苷组合物

Country Status (8)

Country Link
US (2) US20230124503A1 (https=)
EP (2) EP4121061A1 (https=)
JP (2) JP7850670B2 (https=)
CN (2) CN115315264A (https=)
AU (2) AU2021238643A1 (https=)
BR (2) BR112022016241A2 (https=)
CA (2) CA3174698A1 (https=)
WO (2) WO2021185897A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117224553A (zh) * 2023-11-02 2023-12-15 浙江大学 人参皂苷Rg3在制备治疗或预防肠道病毒感染的药物中的应用
CN117752706A (zh) * 2023-12-20 2024-03-26 浙江天皇药业有限公司 西洋参炮制品在制备治疗甲状腺功能减退症药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7850670B2 (ja) * 2020-03-20 2026-04-23 ジボダン エス エー ギンセノシド組成物
JP2023161983A (ja) * 2022-04-26 2023-11-08 石川県公立大学法人 サポニンを含む酪酸産生菌増殖能向上組成物、腸内常在菌増殖能向上組成物、乳酸菌増殖能向上組成物及びビフィズス菌増殖能向上組成物
WO2025261873A1 (en) 2024-06-20 2025-12-26 Givaudan Sa Improvements in or relating to compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278944A1 (en) * 2009-05-04 2010-11-04 Naturex, S.A. Application of american ginseng to enhance neurocognitive function
US20150306119A1 (en) * 2009-05-04 2015-10-29 Naturex, S.A. Application of american ginseng to enhance neurocognitive function
US20160339070A1 (en) * 2013-11-04 2016-11-24 Wen Luan Wendy Hsiao Use of herbal saponins to regulate gut microflora
CN109432304A (zh) * 2018-12-03 2019-03-08 杭州胡庆余堂药业有限公司 一种含铁皮石斛组合物在药物制备中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202731A1 (en) * 2003-04-08 2004-10-14 Gow Robert T. Rosmarinic acid composition
SG11202000258TA (en) 2017-07-18 2020-02-27 Senescence Life Sciences Pte Ltd Compositions and methods for the treatment and prevention of cognitive decline and preservation of neuronal function
CN110613802A (zh) 2018-06-20 2019-12-27 珠海岐微生物科技有限公司 白茅根大黄炭三七组合物及其在调节肠道微生物中的用途
JP7850670B2 (ja) 2020-03-20 2026-04-23 ジボダン エス エー ギンセノシド組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278944A1 (en) * 2009-05-04 2010-11-04 Naturex, S.A. Application of american ginseng to enhance neurocognitive function
US20150306119A1 (en) * 2009-05-04 2015-10-29 Naturex, S.A. Application of american ginseng to enhance neurocognitive function
US20160339070A1 (en) * 2013-11-04 2016-11-24 Wen Luan Wendy Hsiao Use of herbal saponins to regulate gut microflora
CN109432304A (zh) * 2018-12-03 2019-03-08 杭州胡庆余堂药业有限公司 一种含铁皮石斛组合物在药物制备中的应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
C-Z WANG，等: "Correction to: Role of intestinal microbiome in American ginseng-mediated colon cancer prevention in high fat diet-fed AOM/DSS mice", 《CLIN TRANSL ONCOL.》, vol. 20, no. 03, 31 March 2018 (2018-03-31), pages 302 - 312 *
KYUNGHA SHIN，等: "Cereboost™, an American ginseng extract, improves cognitive function via up-regulation of choline acetyltransferase expression and neuroprotection", 《REGUL TOXICOL PHARMACOL.》, 31 July 2016 (2016-07-31), pages 53 - 58 *
LYNNE BELL ，等: "A randomized, placebo-controlled trial investigating the acute and chronic benefits of American Ginseng (Cereboost®) on mood and cognition in healthy young adults, including in vitro investigation of gut microbiota changes as a possible mechanism of action", 《EUR J NUTR.》, vol. 61, no. 1, 15 August 2021 (2021-08-15), pages 413 - 428, XP037673119, DOI: 10.1007/s00394-021-02654-5 *
YONG-KU KIM ，等: "The Microbiota-Gut-Brain Axis in Neuropsychiatric Disorders: Patho-physiological Mechanisms and Novel Treatments", 《CURR NEUROPHARMACOL.》, vol. 16, no. 05, 30 June 2018 (2018-06-30), pages 559 - 573 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117224553A (zh) * 2023-11-02 2023-12-15 浙江大学 人参皂苷Rg3在制备治疗或预防肠道病毒感染的药物中的应用
CN117752706A (zh) * 2023-12-20 2024-03-26 浙江天皇药业有限公司 西洋参炮制品在制备治疗甲状腺功能减退症药物中的应用

Also Published As

Publication number Publication date
CN115315266A (zh) 2022-11-08
JP7850670B2 (ja) 2026-04-23
CA3174699A1 (en) 2021-09-23
WO2021185890A1 (en) 2021-09-23
US20230129389A1 (en) 2023-04-27
BR112022016241A2 (pt) 2022-10-11
JP2023518064A (ja) 2023-04-27
BR112022015826A2 (pt) 2022-10-04
US20230124503A1 (en) 2023-04-20
AU2021238639A1 (en) 2022-09-15
EP4121061A1 (en) 2023-01-25
EP4121076A1 (en) 2023-01-25
CA3174698A1 (en) 2021-09-23
WO2021185897A1 (en) 2021-09-23
AU2021238643A1 (en) 2022-10-20
JP2023519189A (ja) 2023-05-10
JP7808042B2 (ja) 2026-01-28

Similar Documents

Publication Publication Date Title
CN115315264A (zh) 人参皂苷组合物
Tian et al. Digestive characteristics of Hericium erinaceus polysaccharides and their positive effects on fecal microbiota of male and female volunteers during in vitro fermentation
JP5204771B2 (ja) Ｇａｂａ作動性ニューロン賦活剤
CN110636760B (zh) 肠道健康促进组合物
WO2022127934A1 (zh) 人参皂苷在改善肠道菌群结构和/或肠屏障功能的应用
Martirosyan et al. The bioactive compounds of probiotic foods/supplements and their application in managing mental disorders
DK2707010T3 (en) Bacterial strains of the genus Bifidobacterium for use in the treatment of hypercholesterolemia
Liu et al. Microbiome and metabolome integrally reveal the anti-depression effects of Cistanche deserticola polysaccharides from the perspective of gut homeostasis
Kim et al. A prebiotic fiber increases the formation and subsequent absorption of compound K following oral administration of ginseng in rats
US20210121505A1 (en) Compositions and methods for treating inflammatory bowel diseases
Luo et al. Tianhuang formula reduces the oxidative stress response of NAFLD by regulating the gut microbiome in mice
JPWO2008155998A1 (ja) 抗不安抗うつ剤
JP2020533008A (ja) Ｍｅｇａｍｏｎａｓ ｆｕｎｉｆｏｒｍｉｓ及びその適用
JP6280398B2 (ja) Ｇｌｐ−１分泌促進剤
Pan et al. Antiobesity effect of Lactiplantibacillus plantarum fermented barley extracts via the interactions with gut microbiota of the obese adult humans
JP7514926B2 (ja) 個別化腸内細菌叢の多様性を整える機能を有する組成物及び使用
Lan et al. Protective mechanisms of Hovenia dulcis Thunb extracts on acute alcoholism and liver injury
CN103932000B (zh) 一种复合双歧因子的灵芝孢子粉咀嚼片及其制备工艺
Li et al. Hemp seed oil ameliorates CFA-induced rheumatoid arthritis in rats by improving metabolic abnormalities and gut microflora
TWI810645B (zh) 乳桿菌組合物及其改善抗生素造成之焦慮症的用途
CN112956689A (zh) 一种改善便秘的奇异果益生菌的组合物及其应用
Chi Study on biofate and antidepressive mechanism of fructooligosaccharides from Morinda officinalis
WO2026078116A1 (en) Substances for use as a prebiotic or as a medicine
CN116270607A (zh) 一种具有调节肠道菌群作用的组合物
JP2021195326A (ja) 腸内菌叢改善用組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination